Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001744329-24-000003
Filing Date
2024-05-22
Accepted
2024-05-22 16:50:57
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 16219
2 JOINT FILING AGREEMENT, DATED MAY 22, 2024 ex991to13d522_05222024.htm EX-99.1 CHARTER 3678
  Complete submission text file 0001744329-24-000003.txt   21589
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Subject) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-39373 | Film No.: 24974088
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 206 SOUTH AVE MEDIA PA 19063
Business Address 206 SOUTH AVE MEDIA PA 19063 6104241017
SRK FUND I, LP (Filed by) CIK: 0001744329 (see all company filings)

EIN.: 824121679 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D